Total income of the company increased 5.19% at Rs 20.46 crore for Q2FY21
The objective of the trial was to assess the efficacy and safety of SDN-037 in clearing the inflammation and pain
The company will be eligible to receive tiered royalties ranging from 15% to 50% on net sales
Price feed provided by www.nseindia.com
and www.bseindia.com value
addition by www.accordfintech.com.
Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.